{"id":4041,"date":"2025-03-31T18:11:56","date_gmt":"2025-03-31T18:11:56","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/glibenclamide-txt\/"},"modified":"2025-03-31T18:11:56","modified_gmt":"2025-03-31T18:11:56","slug":"glibenclamide-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/glibenclamide-txt\/","title":{"rendered":"Glibenclamide.txt"},"content":{"rendered":"

Glibenclamide <\/h1>\n

CLINICAL USE <\/H3>
\nNon-insulin dependent diabetes mellitus

DOSE IN NORMAL RENAL FUNCTION <\/H3>Initially 5 mg daily (elderly patients \u2013 2.5 mg) adjusted according to response; maximum 15 mg daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :494<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :97<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <5<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.125<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :2.1\u201310\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Initial dose of 1.25\u20132.5 mg once a day. Monitor closely
  • 10 to 20 &nbsp &nbsp : Initial dose of 1.25\u20132.5 mg once a day. Monitor closely
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Initial dose of 1.25\u20132.5 mg once a day. Use cautiously, with continuous monitoring

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Low dialysability. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Analgesics: effects enhanced by NSAIDs\n
  • Antibacterials: effects enhanced by chloramphenicol, sulphonamides, and trimethoprim; effects possibly enhanced by ciprofloxacin and norfloxacin; effect reduced by rifamycins\n
  • Anticoagulants: effect possibly enhanced by coumarins; also possibly changes to INR\n
  • Antifungals: concentration increased by fluconazole and miconazole and possibly voriconazoleBosentan: increased risk of hepatoxicity \u2013 avoid concomitant use\n
  • Ciclosporin: may increase ciclosporin levelsSulfinpyrazone: enhanced effect of sulphonylureas

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>Take with breakfast

    OTHER INFORMATION <\/H4>Metabolites of glibenclamide are only weakly hypoglycaemic; this is not clinically relevant where renal and hepatic functions are normal. If creatinine clearance
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min, accumulation of metabolite and unchanged drug in plasma may cause prolonged hypoglycaemiaCompany information states that use is contraindicated in severe renal impairmentCompensatory excretion via bile in faeces occurs in renal impairment.
    \n","protected":false},"excerpt":{"rendered":"

    Glibenclamide CLINICAL USE Non-insulin dependent diabetes mellitus DOSE IN NORMAL<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4041","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4041"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4041\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}